Netherlands· NL-3c6b48765bd9

Fyremadel, 0,25 mg/0,5 ml oplossing voor injectie in voorgevulde spuit

A ganirelix product containing ganirelixacetaat, registered in Netherlands by Sun Pharmaceutical Industries Europe B.V.. The same ATC class is registered in 17 of our 19 countries.

ATC H01CC01

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about ganirelixacetaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Ganirelix is registered in 17 of 19 countries.

Countries holding a registration under ATC H01CC01 (ganirelix), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
10 of them publish a price we can compare per daily dose

Search ganirelix products by name

Ganirelix · ATC H01CC01

17 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Spainprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: GANIRELIXACETAAT
Manufacturer: Sun Pharmaceutical Industries Europe B.V.
Country: Netherlands (NL)
ATC code: H01CC01
ATC class: Ganirelix
Defined daily dose: 0.25 mg, P
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
111978

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for ganirelix.

Graded by severity as the source publishes them — 7 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check ganirelix against other medicines How interaction checks work

Ganirelix · interactions on record

7 records

7 moderate

Most severe, free to view

Chorionic gonadotrophinG03GA01moderate
Menotropin HMGG03GA02moderate
UrofollitropinG03GA04moderate
GonadorelinH01CA01moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ganirelix in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ganirelix products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

Austria · Ganirelix Astro, Ganirelix Theramex
Belgium · Fyremadel, Ovamex
Bulgaria · Ganirelix Theramex
Czechia · Fyremadel
Germany · Fyremadel, Ganiran
Denmark · Fyremadel, Ganirelix Orifarm
Estonia · Ganirelix Theramex
Spain · Astarté, Fyremadel
Finland · Fyremadel, Ganirelix Orifarm
France · Fyremadel, Ganirelix Eg
United Kingdom (Northern Ireland) · Fyremadel
Greece · Fyremadel, Ovamex
Croatia · Ganireliks Theramex
Hungary · Ganirelix Theramex
Iceland · Ganirelix, Ganirelix Gedeon Richter
Italy · Fyremadel, Ovamex
Liechtenstein · Ganirelix, Ganirelix Gedeon Richter
Lithuania · Ganirelix Theramex
Latvia · Ganirelix Theramex
Norway · Fyremadel, Ganirelix
Poland · Fyremadel, Ovamex
Portugal · Astarté, Fyremadel
Sweden · Fyremadel, Ganirelix Orifarm
Slovenia · Ganireliks Theramex
Slovakia · Fyremadel, Ganirelix Theramex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/7a1c1e0e-5dd9-413b-9cd9-a8b7025ad3d3
GET /v1/drugs/7a1c1e0e-5dd9-413b-9cd9-a8b7025ad3d3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h111978_smpc.pdf",
  "strength": null,
  "atc_label": "Ganirelix",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg111978",
  "excipients": [
    "AZIJNZUUR (E 260), GECONCENTREERD",
    "MANNITOL (D-) (E 421)",
    "NATRIUMHYDROXIDE (E 524)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "GANIRELIXACETAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h111978.pdf",
  "authorised_at": "2013/07/04",
  "procedure_number": "NL/H/2644/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "111978",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about ganirelix.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console